IMV Inc. (IMVIQ)
Company Description
IMV Inc. operates as a clinical-stage immuno-oncology company.
The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers.
The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer.
It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases.
The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Country | Nova Scotia, Canada |
Founded | 2000 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 63 |
CEO | Andrew Hall M.Sc. |
Contact Details
Address: 130 Eileen Stubbs Ave., Suite 19 Dartmouth, A5 B3B 2C4 Nova Scotia, Canada | |
Phone | 9024921819 |
Website | imv-inc.com |
Stock Details
Ticker Symbol | IMVIQ |
Exchange | OTCMKTS |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001734768 |
ISIN Number | CA44974L3011 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Andrew Hall M.Sc. | Chief Executive Officer and Director |
Brittany Davison C.A., CPA | Chief Accounting Officer, Corporate Secretary and Director |
Dr. Jeremy R. Graff Ph.D. | Chief Scientific Officer |
Delphine Davan | Senior Director of Communications and Investor Relations |
Stephan Fiset M.B.A., M.Sc. | Vice President of Clinical Research |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Sep 22, 2023 | 15-12G | Securities registration termination |
Sep 22, 2023 | F-10POS | Filing |
Sep 22, 2023 | F-10POS | Filing |
Sep 22, 2023 | F-10POS | Filing |
Sep 22, 2023 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
Sep 22, 2023 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
Sep 22, 2023 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
Sep 22, 2023 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
Sep 22, 2023 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
Jul 26, 2023 | 6-K | Report of foreign issuer |